China Pharmaceutical Equipment Industry Report, 2011-2012Research in ChinaDecember 20, 2011 80 Pages - SKU: RIC6748612 |
| Countries covered: China In recent years, Chinese pharmaceutical equipment industry has witnessed significant growth in both product quality and technological content, as well as steady rise of sales volume. According to China Association For Pharmaceutical Equipment (CAPE), the gross output value of Chinese pharmaceutical equipment industry hit RMB12.83 billion, up 37.1% YoY, the sales grew 50.1% year on year to RMB12.86 billion, and the total profit increased 68.1% YoY to RMB1.383 billion in 2010. As the products of Chinese pharmaceutical equipment industry are characterized by various types, the enterprises generally adopt the business model of customization, so the industry presents a low degree of market concentration, with CR4 approximating 20%-25%. Presently, domestic major pharmaceutical equipment companies, for instance, Shinva Medical, Tofflon and China Sun Pharmaceutical Machinery, mainly focus on drying, sub-packaging and sterilization facilities. It is expected that the market size of sterilizer, freeze dryer and large volume parenteral (LVP) production line will hit RMB6.5 billion, RMB7.5 billion and RMB1.2 billion respectively in 2013 fueled by factors including the industry transformation caused by new GMP. The development of pharmaceutical equipment industry is closely related with factors including the status quo and market capacity of pharmaceutical industry. Foreign pharmaceutical equipment enterprises, such as Bosch and IMA, basically monopolize foreign-funded pharmaceutical market in China by virtue of their advantages in brand and technology, while domestic pharmaceutical equipment companies dominate domestic-funded pharmaceutical market by their edges in price and localization, for example, the disinfectors and sterilizers of Shinva Medical occupy more than 70% of the market share. However, the share of foreign pharmaceutical equipment companies in the domestic-funded pharmaceutical market is likely to grow. Since 2010, the introduction of new GMP certification and new emission standard for water pollutant and the availability of "Key New Drug Innovation" earmark have stimulated the production scale expansion, existing equipment transformation and upgrading of pharmaceutical companies. From January to September of 2011, the investment in fixed assets of Chinese pharmaceutical industry totaled RMB182.64 billion, rising 39.9% year on year. Driven by the pharmaceutical industry, the sales of pharmaceutical equipment industry also saw a surge. The sales of pharmaceutical equipment industry are estimated to continue rapid growth in 2011-2012 and reach a peak between 2013 and 2014. The report covers the followings:
|
More China Regulation & Policy Reports
China’s Guidebook for Pharmaceutical Patent Protection by
Access China Management Consulting Ltd.
China’s Guidebook for Pharmaceutical Patent Protection is an essential resource for overseas and multinational pharmaceutical companies to achieve a successful patent protection for their intellectual ...
China Chinese Patent Drug Processing Industry, 2012 by
Reports From China
China chinese patent drug processing industry, 2012 is valuable for anyone who wants to invest in the chinese patent drug processing industry, to get Chinese ...
China Drug Patent Inventor Report - 2011 Publication List by
DrugPatentWatch
TheChina Drug Patent Inventor Reportprofiles China-based inventors leading pharmaceutical innovation. Using data on drugs approved from 2000 to 2010, this report provides complete lists of: Top ...
Healthcare Reform in China by
Business Insights
China's pharmaceutical market is growing rapidly in step with it's wider economy. The government aims to extend healthcare coverage to it's 1.3bn citizens, which will ...
Emerging Pharmaceutical Market in China - Forecast to Become The World's Third-Largest Pharmaceutical Market By 2013 by
GBI Research
Emerging Pharmaceutical Market in China - Forecast to Become The World’s Third-Largest Pharmaceutical Market By 2013 Summary GBI Research’s new report, “Emerging Pharmaceutical Market in China - ...
See all reports like this >>
More China Reports
D&B Country RiskLine Report: China by
Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...
Country Report China February 2011 by
Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...
Country Report China January 2011 by
Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...
D&B Country Report: China by
Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...
Wine - BRIC (Brazil, Russia, India, China) Industry Guide by
MarketLine
Datamonitor's Wine - BRIC (Brazil, Russia, India, China) Industry Guide is an essential resource for top-level data and analysis covering the BRIC (Brazil, Russia, India, ...
See all reports like this >>
Related Markets
Regulation & Policy Reports
- Drug Price Cuts in Top Five Countries of Europe - Tougher Reference Pricing Environment and Drug Price Freeze through 2013 Expected to Drive Down Healthcare Costs
- Pricing and Reimbursement in Brazil - Health Technology Assessment (HTA) Studies to Facilitate Setting of Ceiling Prices for New Drugs
- Orphan Disease Therapeutics in Genetic Disorders to 2018 - Emerging Agents in Cystic Fibrosis Offer Strong Opportunities for Investment and Licensing Activity
- Orphan Disease Therapeutics in Genetic Disorders to 2018 - Emerging Agents in Cystic Fibrosis Offer Strong Opportunities for Investment and Licensing Activity
- Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition
